PMID- 25085897
OWN - NLM
STAT- MEDLINE
DCOM- 20150514
LR  - 20211021
IS  - 1549-490X (Electronic)
IS  - 1083-7159 (Print)
IS  - 1083-7159 (Linking)
VI  - 19
IP  - 9
DP  - 2014 Sep
TI  - Investigation of adverse-event-related costs for patients with metastatic breast 
      cancer in a real-world setting.
PG  - 901-8
LID - 10.1634/theoncologist.2014-0059 [doi]
AB  - BACKGROUND: Existing treatments for metastatic breast cancer (mBC) are often 
      effective but can cause adverse events (AEs). This study aimed to identify AEs 
      associated with chemotherapies commonly used in mBC treatment (phase 1) and to 
      quantify the economic impact of these AEs (phase 2). MATERIALS AND METHODS: 
      Patients in phase 1 had at least one claim for therapy for mBC, with at least one 
      episode with single or multiple agents. The most common chemotherapy-related 
      complications were identified using medical and pharmacy claims data. In phase 2, 
      patients meeting study criteria were divided into four treatment cohorts by the 
      line of treatment and chemotherapy received: first-line taxane-treated patients, 
      second-line taxane-treated patients, first-line capecitabine-treated patients, 
      and second-line capecitabine-treated patients. Average monthly AE-related health 
      care costs per cohort were stratified by cost component. Total monthly costs per 
      number of AEs were also calculated. RESULTS: On average, patients in phase 1 (n = 
      1,551) had 2 episodes of treatment, with a mean duration of 131 days. The most 
      frequently noted complications were anemia (50.7% of mBC treatment episodes), 
      bilirubin elevation (26.4%), and leukopenia (24.8%). In phase 2, costs related to 
      AEs were primarily driven by incremental inpatient, outpatient, and pharmacy 
      costs. Increases in average monthly costs ranged from $854 (9.0%) to $5,320 
      (69.5%), according to cohort. Overall costs increased with increasing numbers of 
      AEs. CONCLUSION: Chemotherapy-related AEs in patients with mBC are associated 
      with a substantial economic burden that increases with the number of AEs 
      reported.
CI  - (c)AlphaMed Press.
FAU - Hurvitz, Sara
AU  - Hurvitz S
AD  - University of California Los Angeles, Los Angeles, California, USA; Analysis 
      Group, Inc., Montreal, Quebec, Canada; Genentech Inc., South San Francisco, 
      California, USA; Analysis Group, Inc., Boston, Massachusetts, USA.
FAU - Guerin, Annie
AU  - Guerin A
AD  - University of California Los Angeles, Los Angeles, California, USA; Analysis 
      Group, Inc., Montreal, Quebec, Canada; Genentech Inc., South San Francisco, 
      California, USA; Analysis Group, Inc., Boston, Massachusetts, USA 
      aguerin@analysisgroup.com.
FAU - Brammer, Melissa
AU  - Brammer M
AD  - University of California Los Angeles, Los Angeles, California, USA; Analysis 
      Group, Inc., Montreal, Quebec, Canada; Genentech Inc., South San Francisco, 
      California, USA; Analysis Group, Inc., Boston, Massachusetts, USA.
FAU - Guardino, Ellie
AU  - Guardino E
AD  - University of California Los Angeles, Los Angeles, California, USA; Analysis 
      Group, Inc., Montreal, Quebec, Canada; Genentech Inc., South San Francisco, 
      California, USA; Analysis Group, Inc., Boston, Massachusetts, USA.
FAU - Zhou, Zheng-Yi
AU  - Zhou ZY
AD  - University of California Los Angeles, Los Angeles, California, USA; Analysis 
      Group, Inc., Montreal, Quebec, Canada; Genentech Inc., South San Francisco, 
      California, USA; Analysis Group, Inc., Boston, Massachusetts, USA.
FAU - Latremouille Viau, Dominick
AU  - Latremouille Viau D
AD  - University of California Los Angeles, Los Angeles, California, USA; Analysis 
      Group, Inc., Montreal, Quebec, Canada; Genentech Inc., South San Francisco, 
      California, USA; Analysis Group, Inc., Boston, Massachusetts, USA.
FAU - Wu, Eric Q
AU  - Wu EQ
AD  - University of California Los Angeles, Los Angeles, California, USA; Analysis 
      Group, Inc., Montreal, Quebec, Canada; Genentech Inc., South San Francisco, 
      California, USA; Analysis Group, Inc., Boston, Massachusetts, USA.
FAU - Lalla, Deepa
AU  - Lalla D
AD  - University of California Los Angeles, Los Angeles, California, USA; Analysis 
      Group, Inc., Montreal, Quebec, Canada; Genentech Inc., South San Francisco, 
      California, USA; Analysis Group, Inc., Boston, Massachusetts, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140801
PL  - England
TA  - Oncologist
JT  - The oncologist
JID - 9607837
RN  - 0 (Bridged-Ring Compounds)
RN  - 0 (Taxoids)
RN  - 0W860991D6 (Deoxycytidine)
RN  - 1605-68-1 (taxane)
RN  - 6804DJ8Z9U (Capecitabine)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Aged
MH  - Breast Neoplasms/drug therapy/*economics/epidemiology
MH  - Bridged-Ring Compounds/economics/therapeutic use
MH  - Capecitabine
MH  - Costs and Cost Analysis/*economics
MH  - Deoxycytidine/analogs & derivatives/economics/therapeutic use
MH  - Drug-Related Side Effects and Adverse Reactions/*economics/epidemiology
MH  - Female
MH  - Fluorouracil/analogs & derivatives/economics/therapeutic use
MH  - *Health Care Costs
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Taxoids/economics/therapeutic use
PMC - PMC4153460
OTO - NOTNLM
OT  - Breast neoplasms
OT  - Costs and cost analysis
OT  - Drug-related side effects and adverse reactions
OT  - Neoplasm metastasis
COIS- Disclosures of potential conflicts of interest may be found at the end of this 
      article.
EDAT- 2014/08/03 06:00
MHDA- 2015/05/15 06:00
PMCR- 2015/09/01
CRDT- 2014/08/03 06:00
PHST- 2014/08/03 06:00 [entrez]
PHST- 2014/08/03 06:00 [pubmed]
PHST- 2015/05/15 06:00 [medline]
PHST- 2015/09/01 00:00 [pmc-release]
AID - theoncologist.2014-0059 [pii]
AID - T1459 [pii]
AID - 10.1634/theoncologist.2014-0059 [doi]
PST - ppublish
SO  - Oncologist. 2014 Sep;19(9):901-8. doi: 10.1634/theoncologist.2014-0059. Epub 2014 
      Aug 1.